Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Post by kingposton Feb 11, 2015 7:51pm
169 Views
Post# 23420229

from generic co Lannett today ---$86 bil new generics coming

from generic co Lannett today ---$86 bil new generics coming

"According to Lannett, $86 billion of brand drugs are coming off patent through 2017. Baby boomers should be a strong growth driver for the drug industry in the following years. The generics industry is on a secular growth path and Lannett will certainly benefit from those trends. Lannett currently has 39 marketed products, 43 products in development and 20 products pending approval. The 20 products that are pending approval had 2013 sales (branded and generic) around $2.8 billion. If Lannett captures just a couple of percentage points of the addressable market, the potential revenues from these products could exceed $100 million in the next couple of years.

The most important market for Lannett in the following years should be the controlled substance market. The controlled substance market in the U.S. had $26 billion in sales in 2013 with the generic portion contributing $9.7 billion. This market has a high barrier to entry as it is controlled by the DEA."

Bullboard Posts